Clinton Names New NCI Director

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

WASHINGTON--President Clinton has appointed Dr. Richard D. Klausner as director of the National Cancer Institute. Dr. Klausner has served as chief, Cell Biology and Metabolism Branch, National Institute of Child Health and Human Development, since 1984. He earned his undergraduate degree at Yale and his MD from Duke.

WASHINGTON--President Clinton has appointed Dr. Richard D. Klausneras director of the National Cancer Institute. Dr. Klausner hasserved as chief, Cell Biology and Metabolism Branch, NationalInstitute of Child Health and Human Development, since 1984. Heearned his undergraduate degree at Yale and his MD from Duke.

In a statement of congratulations from the American Society ofClinical Oncology, John H. Glick, MD, president, called Dr. Klausnera "distinguished molecular biologist . . . with an impressiverecord of scientific and administrative accomplishments at theNIH."

Dr. Harold E. Varmus, NIH director, said that Dr. Klausner "bringsto this important post an extraordinary record of scientific achievement,admirable personal qualities, and a firm commitment to advancingthe nation's health through vigorous and innovative science. Iam sure that Dr. Klausner will provide the leadership that NIH'slargest and most visible institute needs as it carries forwardthe fight against cancer.

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
7 experts are featured in this series.
Related Content